Kabra Drugs Ltd Stock Price Today (NSE: KABRADG)
Fundamental Score
Kabra Drugs Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Kabra Drugs Ltd share price today is ₹22.51, down 1.75% on NSE/BSE as of 18 June 2026. Kabra Drugs Ltd (KABRADG) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹74.23 (Cr). The 52-week high for KABRADG share price is ₹35.52 and the 52-week low is ₹12.21. At a P/E ratio of 62.38x, KABRADG is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of -8.47% and a debt-to-equity ratio of 0.02.
Kabra Drugs Ltd Share Price Chart — NSE/BSE Historical Performance
Kabra Drugs Ltd share price chart: 1.49% return over the past month. 52-week high ₹35.52, 52-week low ₹12.21.
Kabra Drugs Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹23.00 | ₹23.86 | ₹22.15 | ₹22.51 | 87.51K (Cr) | |
| ₹25.90 | ₹25.90 | ₹22.61 | ₹22.91 | 2.16L (Cr) | |
| ₹25.44 | ₹25.44 | ₹23.16 | ₹24.40 | 1.84L (Cr) | |
| ₹24.31 | ₹25.55 | ₹24.31 | ₹25.22 | 1.55L (Cr) | |
| ₹24.38 | ₹26.30 | ₹23.63 | ₹24.22 | 1.15L (Cr) | |
| ₹24.27 | ₹25.80 | ₹23.56 | ₹24.41 | 54.05K (Cr) | |
| ₹24.88 | ₹24.93 | ₹23.60 | ₹24.01 | 76.99K (Cr) | |
| ₹25.96 | ₹25.96 | ₹23.35 | ₹24.03 | 1.21L (Cr) | |
| ₹25.35 | ₹27.49 | ₹24.30 | ₹25.13 | 67.53K (Cr) | |
| ₹23.78 | ₹25.40 | ₹23.70 | ₹25.23 | 47.05K (Cr) |
Kabra Drugs Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹25.90 | ₹25.90 | ₹22.15 | ₹22.51 | -13.09% | |
| ₹26.03 | ₹28.18 | ₹23.16 | ₹24.40 | -6.26% | |
| ₹24.58 | ₹29.45 | ₹23.30 | ₹26.03 | +5.90% | |
| ₹29.15 | ₹32.07 | ₹24.50 | ₹24.58 | -15.68% | |
| ₹28.90 | ₹35.52 | ₹27.64 | ₹30.52 | +5.61% | |
| ₹31.27 | ₹33.00 | ₹25.64 | ₹28.62 | -8.47% | |
| ₹32.64 | ₹32.66 | ₹25.46 | ₹30.55 | -6.40% | |
| ₹19.37 | ₹31.15 | ₹18.50 | ₹31.11 | +60.61% | |
| ₹17.85 | ₹20.49 | ₹15.50 | ₹18.92 | +5.99% | |
| ₹19.44 | ₹21.00 | ₹17.08 | ₹17.69 | -9.00% | |
| ₹20.51 | ₹21.41 | ₹17.40 | ₹18.52 | -9.70% | |
| ₹16.34 | ₹22.77 | ₹16.34 | ₹20.11 | +23.07% |
AI Research Briefing
Powered by Gemini · 2026-04-17
Zero promoter holding, stretched valuation, and microcap illiquidity make Kabra Drugs a high-risk gamble, not an investment.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Kabra Drugs board will meet on April 21, 2026, to consider Ms. Monam Kapoor as an Additional Director and major diversification plans. India Pharma 2026 concluded on April 15, 2026, with calls for enhanced funding and infrastructure to accelerate pharmaceutical innovation.
CORE STORY (THE REAL GAME)
- Q3FY26 PAT jump of 578% YoY
- Revenue increased 53.9% QoQ in Q3FY26
- Agreement to appoint 200 channel partners
- Successful diversification into medical equipment manufacturing
- Significant order wins in the medical equipment segment
- Positive regulatory approvals for new business streams
- Zero promoter holding
- History of losses and negative free cash flow of ₹-5.7 Cr over 5 years
- Microcap illiquidity: high price volatility and potential for manipulation
Zero FII, DII, or Promoter holding indicates a lack of institutional confidence.
The Indian pharmaceutical industry is undergoing a strategic shift towards innovation and domestic manufacturing, presenting both opportunities and challenges.
Kabra Drugs signed an agreement with MR Franchise to appoint 200 channel partners nationwide.
No: Free Cash Flow 5Y: ₹-5.7 Cr.
Kabra Drugs' future hinges on successful diversification and execution of its expansion plans. Failure to achieve these goals could lead to a significant correction in the stock price.
Primary Thesis Risk
Lack of promoter commitment and stretched valuation make this a high-risk, low-conviction play.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Kabra Drugs Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Kabra Drugs Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of KABRADG across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Robust Profit Growth (560.00%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Conservative Debt Levels (D/E: 0.02)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Below-Average Return on Equity (-8.47%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-7.82%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 62.38x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Negative Free Cash Flow (₹-5.70 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Low Promoter Commitment (0.00%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Kabra Drugs Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Kabra Drugs Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Kabra Drugs LtdKabra Drugs Ltd...Selected✓ KABRADG • 524322 | 10.5/100 | ₹22.51₹23 | ₹74.23₹74.23 | 62.38Average 62.4 Average | -8.47%Poor -8.47% Poor | -7.82%Poor -7.82% Poor | 0.02Excellent 0.0 Excellent | — — | — — | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1796.50₹1797 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6553.50₹6554 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4350.40₹4350 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1390.30₹1390 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1290.40₹1290 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2262.90₹2263 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹1091.20₹1091 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2320.20₹2320 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1433.70₹1434 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5314.50₹5315 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Kabra Drugs Ltd Quarterly Performance
Latest quarterly metrics for KABRADG — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
N/A
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
560.00%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Kabra Drugs Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for KABRADG — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Kabra Drugs Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Kabra Drugs Ltd (KABRADG) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Kabra Drugs Ltd
About KABRADG (Kabra Drugs Ltd)
Kabra Drugs Ltd is a dormant entity in the pharmaceutical sector, currently holding no active operational functions. Historically, Kabra Drugs Ltd participated in the manufacturing... and commercial exchange of pharmaceutical related goods, though these activities have ceased. The company's original ambition focused on permaculture, a sustainable agricultural system, hinting at an earlier diversification strategy into eco-friendly practices. This suggests a potential for incorporating environmentally conscious manufacturing processes should the company choose to reactivate. Established in 1989, Kabra Drugs Ltd has maintained its headquarters in Chennai, India, as its registered base. While currently inactive, the company's registration as a pharmaceutical entity provides a potential framework for future development within the industry. The existing infrastructure and knowledge base, however outdated, could offer a foundation for re-entry into the market, either through internal restructuring or external collaborations. The company's long-standing presence, even in dormancy, suggests a level of legacy and brand awareness that could be leveraged in any future endeavors. The current state of Kabra Drugs Ltd necessitates a significant reevaluation of its business model and strategic direction should it seek to revitalize its operations. Market analysis, investment in updated technology, and a renewed focus on regulatory compliance would be essential to compete effectively in the modern pharmaceutical landscape. The shift from active engagement to dormancy represents a turning point in the company's history, demanding bold leadership and innovative strategies to navigate the challenges and opportunities that lie ahead.
Company Details
Key Leadership
KABRADG Share Price: Frequently Asked Questions
What is the current share price of Kabra Drugs Ltd?
Kabra Drugs Ltd (KABRADG) trades at ₹22.51 on NSE and BSE. Market cap ₹74.23 (Cr). Educational data only.
What is the P/E ratio of Kabra Drugs Ltd?
Kabra Drugs Ltd has a P/E of 62.38x vs industry average 31.77x.
What is the Bull Run score for Kabra Drugs Ltd?
Kabra Drugs Ltd has a Bull Run score of 10.5/100 based on 25+ financial parameters.
Does Kabra Drugs Ltd pay dividends?
Kabra Drugs Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Kabra Drugs Ltd?
Kabra Drugs Ltd has ROE of -8.47%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Kabra Drugs Ltd?
Kabra Drugs Ltd has debt-to-equity of 0.02.
Is Kabra Drugs Ltd a good investment?
Bull Run gives Kabra Drugs Ltd a score of 10.5/100. This is not investment advice — consult a SEBI-registered advisor.